OCUL Stock - Ocular Therapeutix, Inc.
Unlock GoAI Insights for OCUL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $63.72M | $58.44M | $51.49M | $43.52M | $17.40M |
| Gross Profit | $58.10M | $53.16M | $46.95M | $39.12M | $15.32M |
| Gross Margin | 91.2% | 91.0% | 91.2% | 89.9% | 88.0% |
| Operating Income | $-171,781,000 | $-82,382,000 | $-78,654,000 | $-78,037,000 | $-62,847,000 |
| Net Income | $-193,506,000 | $-80,736,000 | $-71,038,000 | $-6,553,000 | $-155,636,000 |
| Net Margin | -303.7% | -138.1% | -138.0% | -15.1% | -894.3% |
| EPS | $-1.22 | $-1.09 | $-1.04 | $-1.05 | $-2.56 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 15th 2025 | Chardan Capital Markets | Initiation | Buy | $21 |
| April 8th 2025 | William Blair | Initiation | Outperform | - |
| March 18th 2025 | RBC Capital Mkts | Initiation | Outperform | $17 |
| March 11th 2025 | Needham | Initiation | Buy | $15 |
| October 16th 2024 | Scotiabank | Initiation | Sector Outperform | - |
| June 20th 2024 | TD Cowen | Upgrade | Buy | $11← $7 |
| May 31st 2024 | Piper Sandler | Resumed | Overweight | $15 |
| February 9th 2024 | BofA Securities | Initiation | Buy | $15 |
| April 21st 2023 | Robert W. Baird | Initiation | Outperform | $18 |
| August 10th 2022 | Berenberg | Resumed | Buy | $15 |
Earnings History & Surprises
OCULEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.33 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.39 | $-0.37 | +5.1% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.35 | $-0.39 | -11.4% | ✗ MISS |
Q2 2025 | May 5, 2025 | $-0.29 | $-0.37 | -27.6% | ✗ MISS |
Q1 2025 | Mar 3, 2025 | $-0.24 | $-0.29 | -20.8% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.23 | $-0.26 | -13.0% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q2 2024 | May 7, 2024 | $-0.18 | $-0.24 | -33.3% | ✗ MISS |
Q1 2024 | Mar 11, 2024 | $-0.28 | $-0.28 | 0.0% | = MET |
Q4 2023 | Nov 7, 2023 | $-0.27 | $-0.51 | -88.9% | ✗ MISS |
Q3 2023 | Aug 7, 2023 | $-0.29 | $-0.27 | +6.9% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $-0.27 | $-0.31 | -14.8% | ✗ MISS |
Q1 2023 | Mar 6, 2023 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.23 | $-0.30 | -30.4% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.23 | $-0.28 | -21.7% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.25 | $-0.22 | +12.0% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.23 | $-0.23 | 0.0% | = MET |
Q4 2021 | Nov 8, 2021 | $-0.26 | $-0.23 | +11.5% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.20 | $-0.25 | -25.0% | ✗ MISS |
Latest News
Chardan Capital Maintains Buy on Ocular Therapeutix, Maintains $21 Price Target
📈 PositiveNeedham Reiterates Buy on Ocular Therapeutix, Maintains $20 Price Target
📈 PositiveOcular Therapeutix shares are trading higher after the company announced plans to accelerate its NDA submission timeline for AXPAXLI in Wet AMD. HC Wainwright raised its price target on the stock from $19 to $21.
📈 PositiveHC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $21
📈 PositiveOcular Therapeutix Intends To Submit An Fda New Drug Application For Axpaxli For Wet Age-related Macular Degeneration Following Year One Data, If Positive, From Its Ongoing SOL-1 Phase 3 Trial For Which Data Are On Track For Q1 Of 2026
➖ NeutralHC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $19 Price Target
📈 PositiveOcular Therapeutix Begins Major Trial On Drug That Could Prevent Blindness In Working-Age Diabetics
📈 PositiveChardan Capital Maintains Buy on Ocular Therapeutix, Maintains $21 Price Target
📈 PositiveOcular Therapeutix Q3 EPS $(0.38) Misses $(0.37) Estimate, Sales $14.544M Miss $14.627M Estimate
📉 NegativeTD Cowen Maintains Buy on Ocular Therapeutix, Raises Price Target to $20
📈 PositiveOcular Therapeutix shares are trading higher after HC Wainwright & Co maintained its Buy rating on the stock and raised its price target from $15 to $19.
📈 PositiveHC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $19
📈 PositivePiper Sandler Maintains Overweight on Ocular Therapeutix, Raises Price Target to $31
📈 PositiveBaird Maintains Outperform on Ocular Therapeutix, Raises Price Target to $24
📈 PositiveChardan Capital Maintains Buy on Ocular Therapeutix, Maintains $21 Price Target
📈 PositiveNeedham Maintains Buy on Ocular Therapeutix, Raises Price Target to $20
📈 PositiveJMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $29
📈 PositiveOCUL stock has given up its prior gain. Ocular Therapeutix shares were trading higher after the company raised $475M in a stock offering to fund eye disease drug trials.
📉 NegativeOcular Therapeutix shares are trading higher after the company raised $475M in a stock offering to fund eye disease drug trials.
📈 PositiveOcular Therapeutix Raises $475M In Stock Offering Of 37.9M Shares At $12.53/Share To Fund Eye Disease Drug Trials
➖ NeutralFrequently Asked Questions about OCUL
What is OCUL's current stock price?
What is the analyst price target for OCUL?
What sector is Ocular Therapeutix, Inc. in?
What is OCUL's market cap?
Does OCUL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to OCUL for comparison